Johnson & Johnson (NYSE: JNJ) will present data from two major studies supporting the performance of its recently FDA-approved TECNIS PureSee intraocular lens (IOL) at the 2026 American Society of ...
The Tecnis PureSee extended depth of focus IOL provides good distance and intermediate vision, according to a real-world study presented at the American Society of Cataract and Refractive Surgery ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Johnson & Johnson (JNJ) is back in the spotlight after presenting extensive clinical ...
JACKSONVILLE, Fla. - Johnson & Johnson (NYSE:JNJ) presented clinical data on its TECNIS PureSee intraocular lens at the American Society of Cataract and Refractive Surgery Annual Meeting, held April ...
Johnson & Johnson presented multi-region clinical results at ASCRS 2026 showing its FDA-approved TECNIS PureSee intraocular lens delivers exceptional distance and intermediate vision, high contrast ...
Hosted on MSN
FDA approves Tecnis PureSee lens to cut glare risk
Johnson & Johnson has gained FDA approval for its Tecnis PureSee intraocular lens, the first extended depth-of-focus lens designed to maintain contrast sensitivity while minimizing glare and halos.
Johnson & Johnson CEO Joaquin Duato did not mince words when he described the state of the company Tuesday. “Our success is fueled by the strongest portfolio and pipeline in the history of Johnson & ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results